Background Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19)
remain elusive. Among them, convalescent plasma administered to hospitalized …

Background Therapies to interrupt progression of early COVID-19 remain elusive. Among
them, convalescent plasma in hospitalized patients was unsuccessful, perhaps because …

Background A first-dose of various vaccines provides acceptable protection against infections
by SARS-CoV-2 and evolution to the most severe forms of COVID-19. The recombinant …

Massive vaccination offers great promise for halting the global COVID-19 pandemic. However,
the limited supply and uneven vaccine distribution create an urgent need to optimize …

Background Convalescent plasma, widely utilized in viral infections that induce neutralizing
antibodies, has been proposed for COVID-19, and preliminary evidence shows that it might …

Background Although paediatric clinical presentations of COVID-19 are usually less severe
than in adults, serious illness and death have occurred. Many countries started the …

Heterologous vaccination against coronavirus disease 2019 (COVID-19) provides a rational
strategy to rapidly increase vaccination coverage in many regions of the world. Although …

Background After primary vaccination schemes with rAd26-rAd5 (Sputnik V), ChAdOx1
nCoV-19, BBIBP-CorV or heterologous combinations, the effectiveness of homologous or …

This is a multicenter cohort study including consecutive, hospitalized patients ≥18 years, with
moderate to severe COVID-19, carried out to evaluate the relationship between the timing …

Recent studies have shown a temporal increase in the neutralizing antibody potency and
breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent …